Literature DB >> 6316414

New diphosphonate compounds for skeletal imaging: comparison with methylene diphosphonate.

G Subramanian, J G McAfee, F D Thomas, T A Feld, C Zapf-Longo, E Palladino.   

Abstract

Three-hour biodistribution of Tc-99m complexes of six diphosphonates was compared in rabbits with tibial lesions to determine which was best for detection of focal bone lesions. Sr-85 was used as a standard. N,N-dimethylaminomethylene diphosphonate (DMAD) was the only agent with a higher lesion/normal bone ratio than methylene diphosphonate (MDP), attributable to lower concentration in normal bone. Hydroxymethane diphosphonate (HDP) and 2,3-dicarboxypropane-1, 1-diphosphonate (DPD) demonstrated higher concentration than MDP in normal bone without improving lesion contrast. They also exhibited much higher uptake in the liver and kidney, as well as muscle and red marrow in the case of DPD. None was superior to MDP as an all-purpose skeletal agent, though others may be better for specific applications.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6316414     DOI: 10.1148/radiology.149.3.6316414

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  3 in total

1.  Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases.

Authors:  W Y Lin; C P Lin; S J Yeh; B T Hsieh; Z T Tsai; G Ting; T C Yen; S J Wang; F F Knapp; M G Stabin
Journal:  Eur J Nucl Med       Date:  1997-06

2.  Technetium-1,2-dihydroxy-1,2-bis(dihydroxyphosphinyl)ethane (99mTc-DHPE). A promising new skeletal imaging agent.

Authors:  S C Archimandritis; A K Tsolis
Journal:  Eur J Nucl Med       Date:  1987

3.  Bone-seeking nanoplatform co-delivering cisplatin and zoledronate for synergistic therapy of breast cancer bone metastasis and bone resorption.

Authors:  Yanjuan Huang; Zhanghong Xiao; Zilin Guan; Zishan Zeng; Yifeng Shen; Xiaoyu Xu; Chunshun Zhao
Journal:  Acta Pharm Sin B       Date:  2020-06-19       Impact factor: 11.413

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.